Organogenesis (NASDAQ:ORGO) Shares Down 11.3% - What's Next?

Key Points

• Organogenesis shares dropped by 11.3% to $4.15, with trading volume significantly down to 141,897 shares, compared to an average of 1,345,838 shares.
• Analysts maintain a generally positive outlook, with BTIG Research reaffirming a "buy" rating and setting a target price of $7.00, while Cantor Fitzgerald increased their target to $9.00.
• The company's recent earnings report revealed a loss of ($0.09) per share, which missed the consensus estimate, alongside revenue of $101.01 million, below the expected $104.75 million.

Organogenesis (NASDAQ:ORGO - Get Free Report)'s share price fell 11.3% during trading on Friday . The stock traded as low as $4.23 and last traded at $4.15. 141,897 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 1,345,838 shares. The stock had previously closed at $4.68.

Analysts Set New Price Targets

Several brokerages have recently commented on ORGO. BTIG Research reaffirmed a "buy" rating and issued a $7.00 target price on shares of Organogenesis in a research report on Friday. Cantor Fitzgerald lifted their price objective on Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.33.

Organogenesis Price Performance

The stock has a market capitalization of $520.76 million, a P/E ratio of -29.39 and a beta of 1.75. The firm has a 50 day moving average of $4.77 and a 200-day moving average of $4.26.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The company had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ORGO. Farther Finance Advisors LLC bought a new stake in shares of Organogenesis during the 2nd quarter valued at $35,000. Ground Swell Capital LLC bought a new stake in shares of Organogenesis in the 2nd quarter valued at $39,000. Merit Financial Group LLC bought a new stake in shares of Organogenesis in the 1st quarter valued at $45,000. Walleye Capital LLC bought a new stake in shares of Organogenesis in the 2nd quarter valued at $45,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Organogenesis in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.